Arcus Biosciences RCUS Business Segments — Total revenues
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcus Biosciences in its filing.
Tagged under the XBRL concept us-gaap:Revenues.
The official record: Arcus Biosciences’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Arcus Biosciences's business segments — total revenues.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Arcus Biosciences's business segments — total revenues?
- Arcus Biosciences (RCUS) reported business segments — total revenues of $17M in Q1 2026.
- How has Arcus Biosciences's business segments — total revenues changed year-over-year?
- Arcus Biosciences's business segments — total revenues decreased by 39.3% year-over-year, from $28M to $17M.
- What is the long-term trend for Arcus Biosciences's business segments — total revenues?
- Over 3 years (2022 to 2025), Arcus Biosciences's business segments — total revenues has grown at a 30.2% compound annual growth rate (CAGR), from $112M to $247M.
- What does business segments — total revenues mean?
- Represents the total gross income generated by the primary business segment through its core operations, including product sales, licensing fees, and collaboration revenue. This metric serves as a key indicator of the segment's market traction and commercial success in its therapeutic focus areas.